申请人:Takeda Pharmaceutical Company Limited
公开号:EP1593681A1
公开(公告)日:2005-11-09
A compound of the formula:
wherein R1 is a 5- or 6-membered ring;
Z1 is a 5- or 6-membered aromatic ring;
Z2 is a group of -Z2a-W2-Z2b-, wherein Z2a and Z2b are each O, S(O)q (wherein q is 0, 1 or 2), an imino group, or a bond; and W2 is an alkylene chain;
W is a group represented by
wherein R3 and R3' are each a hydrogen atom, a lower alkyl group, or a lower alkoxy group; X is CH or N; n and n' are each an integer of 0 or 1 to 4; m and m' are each 1 or 2; Y is O, S(O)p (wherein p is 0, 1 or 2), CH2 or NR4 (wherein R4 is a hydrogen atom, a lower alkyl group, or a lower acyl group); and
R2 is (1) an amino group, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atommay be converted to a quaternary ammonium or an oxide; or a salt thereof.
The compound exhibits excellent CCR antagonist activity against CCR5, and is useful as a prophylactic and/or therapeutic agent for HIV infection in human peripheral blood mononuclear cells, especially for AIDS.
式中的化合物
其中 R1 是 5 或 6 元环;
Z1 是 5 或 6 元芳香环
Z2 是-Z2a-W2-Z2b-的基团,其中 Z2a 和 Z2b 分别是 O、S(O)q(其中 q 是 0、1 或 2)、亚氨基或键;以及 W2 是亚烷基链;
W 是由以下各项表示的基团
其中 R3 和 R3'各自是氢原子、低级烷基或低级烷氧基;X 是 CH 或 N;n 和 n'各自是 0 或 1 至 4 的整数;m 和 m'各自是 1 或 2;Y 是 O、S(O)p(其中 p 是 0、1 或 2)、CH2 或 NR4(其中 R4 是氢原子、低级烷基或低级酰基);以及
R2 是(1)氨基,其中的氮原子可转化为季铵或氧化物,或(2)含氮杂环基团,其中可包含一个硫原子或一个氧原子作为成环原子,其中的氮原子可转化为季铵或氧化物;或其盐。
该化合物对 CCR5 具有优异的 CCR 拮抗剂活性,可用作人类外周血单核细胞中 HIV 感染的预防和/或治疗剂,特别是艾滋病的预防和/或治疗剂。